CFI-400945 Fumarate - CAS 1616420-30-4
Catalog number:
1616420-30-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C37H38N4O7
Molecular Weight:
650.72
COA:
Inquire
Targets:
Polo-like Kinase (PLK)
Description:
The fumarate salt form of CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and inducing apoptosis. It is still under Phase I trial against solid tumors.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
CFI400945; CFI 400945; CFI-400945; CFI-400945 fumarate; (1R,2S)-2-(3-((E)-4-(((2S,6R)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
Storage:
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
MSDS:
Inquire
Quality Standard:
In-house standard
Quantity:
Milligram-Grams
Canonical SMILES:
O=C(NC1=C2C=C(C=C1)OC)[C@@]32[C@@H](C3)C4=CC5=C(C(/C=C/C6=CC=C(C=C6)CN7C[C@@H](O[C@@H]
Current Developer:
UHN
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Polo-like Kinase (PLK) Products


CAS 592542-59-1 Rigosertib

Rigosertib
(CAS: 592542-59-1)

Rigosertib, a synthetic benzyl styryl sulfone, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM).

CAS 1034616-18-6 NMS-1286937

NMS-1286937
(CAS: 1034616-18-6)

NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-l...

TAK-960 dihydrochloride

TAK-960 is an orally available, potent and selective PLK1 inhibitor that was in a phase I clinical trial in patients with advanced non-hematologic malignancies.

CAS 321688-88-4 Poloxin

Poloxin
(CAS: 321688-88-4)

Poloxin is the first small-molecule inhibitor specifically targeting the function of the Plk1 PBD. Poloxin induces centrosome fragmentation and abnormal spindle...

CAS 244240-24-2 LFM-A13

LFM-A13
(CAS: 244240-24-2)

LFM-A13 is a specific Bruton's tyrosine kinase (BTK) with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and I...

CAS 929095-18-1 GSK-461364

GSK-461364
(CAS: 929095-18-1)

GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kin...

TAK-960 hydrochloride
(CAS: 1137868-96-2)

The hydrochloride salt form of TAK-960, a newly studied selective PLK1 inhibitor, might have potential effect in inhibiting proliferation of sorts of cancer cel...

CFI-400945 Fumarate
(CAS: 1616420-30-4)

The fumarate salt form of CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and ...

CAS 592542-60-4 Rigosertib sodium

Rigosertib sodium
(CAS: 592542-60-4)

Rigosertib, a synthetic benzyl styryl sulfone, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM).

CAS 1052532-15-6 SBE-13 HCl

SBE-13 HCl
(CAS: 1052532-15-6)

SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. SBE13 does not effect the activi...

CAS 131247-39-8 ON1231320

ON1231320
(CAS: 131247-39-8)

ON1231320, also known as GBO-006, was found to be a specific Polo like kinase 2 (PLK2) inhibitor when profiled against a panel of 288 wild-type, 55 mutant and 1...

CAS 1062243-51-9 Ro5203280

Ro5203280
(CAS: 1062243-51-9)

Ro5203280 is a small-molecular PLK1 inhibitor. Ro5203280 shows a high efficacy for suppressing nasopharyngeal carcinoma growth with low toxicity in mouse studie...

CAS 660868-91-7 GW843682X

GW843682X
(CAS: 660868-91-7)

GW843682X is a cell-permeable thiophene-benzimidazole compound that acts a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM(PLK1) and 9.1 nM(PLK3).

CAS 1228960-69-7 MLN0905

MLN0905
(CAS: 1228960-69-7)

MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lin...

CFI-400945
(CAS: 1338806-76-0)

CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and inducing apoptosis. It is ...

CAS 1137868-52-0 TAK-960

TAK-960
(CAS: 1137868-52-0)

TAK-960 is an orally available PLK1 inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing ...

CAS 755038-65-4 Volasertib

Volasertib
(CAS: 755038-65-4)

BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk) with an IC50 of 0 .87 nM and EC50 of 11-37 nM on a panel of cancer cell lines, w...

CAS 173529-46-9 HMN-214

HMN-214
(CAS: 173529-46-9)

HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kin...

SBE13
(CAS: 775294-82-1)

SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. Its IC50 value is 0.2 nM. It doe...

Quick Inquiry

Verification code

Featured Items